|Articles|February 1, 2019
- Pharmaceutical Executive-02-01-2019
- Volume 39
- Issue 2
Pharmaceutical Executive, February 2019 Issue (PDF)
Click the title above to open the Pharmaceutical Executive February 2019 issue in an interactive PDF format.
Advertisement
Articles in this issue
about 7 years ago
Q&A: Regulatory Reform in Chinaabout 7 years ago
China: A Change in Attitudeabout 7 years ago
New Roads to Chinaabout 7 years ago
Closing the Pharma and Digital Health Divideabout 7 years ago
A Leading Man’s Next Actabout 7 years ago
Two Steps Forwardabout 7 years ago
Let the Drug Pricing Games Beginabout 7 years ago
Mixed Outlook for China Life Sciencesabout 7 years ago
CFIUS Reform’s Impact on Biopharmaabout 7 years ago
Op-Ed: Opening the Golden DoorNewsletter
Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Asembia ASX26: Adjusting Strategies to Adapt to an Uncertain Global Political and Regulatory Market
2
Which Supply Chains are Most Exposed by Disruptions in The Strait of Hormuz?
3
Teva Enters $900 Million Agreement to Acquire Emalex
4
Asembia AXS26 Summit: The Future of High-Cost Specialty Drugs
5